Email

citrine.elatrash@bcm.edu

Positions

Clinical Research Coordinator III

Pediatrics - Nutrition
Baylor College of Medicine
Houston, US

Addresses

Children Nutrition Research Center (Lab)

1100 BATES
Sisley's Lab
Houston, TX 77030
United States
Phone: (713) 798-9316
Fax: (713) 798-7098
Citrine.Elatrash@bcm.edu
https://www.bcm.edu/people-search/citrine-elatrash-59141

Children Nutrition Research Center (Clinic)

1100 BATES
Sisley's Lab
Houston, TX 77030
United States
Phone: (713) 798-9316
Fax: (713) 798-7098
Citrine.Elatrash@bcm.edu
https://www.bcm.edu/people-search/citrine-elatrash-59141

Children Nutrition Research Center (Office)

1100 BATES
Sisley's Lab
Houston, TX 77030
United States
Phone: (713) 798-9316
Fax: (713) 798-7098
Citrine.Elatrash@bcm.edu
https://www.bcm.edu/people-search/citrine-elatrash-59141

Education

MBChB from University of Tripoli

04/2006 - Tripoli, Tripoli Libya

Certifications

CCRP

#61515 (02/01/2018 - 02/01/2021)

SOCRA

Professional Statement

Passionate, enthusiastic, and committed to clinical research with a strong background in
clinical research operations and the medical field. Possess in-depth knowledge and understanding
of Human Research Protection Regulation, including 45 CFR 46, 21 CFR 50, 21 CFR 56, 21 CFR
312, 21 CFR 218, GCP, ICH, and clinical trial methodology.

Projects

Genetic Disorders of Obesity Program (CGDO

(04/2021 - present)

This project is for collecting information on all children who come into the CGDO clinic. The aim is to use this information to determine better strategies for identifying children who would benefit from genetic testing, how children respond to therapies, and how to better support parents. This project also includes collecting cheek swabs of children and their parents for genetic analysis by future studies.

Setmelanotide Phase 2 and Phase 3 Treatment Trials in Patients with Rare Genetic Disorders of Obesity

(08/2020 - present)

This project is several clinical trials that have a purpose to determine the effect of setmelanotide (RM-493) on weight, hunger assessments, and other factors in patients with rare genetic disorders of obesity. • RM-493-014; Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with Rare Genetic Disorders of Obesity (currently closed for enrollment) • RM-493-022; Long-Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated with Genetic Defects Upstream of the MC4 Receptor in the Leptin-Melanocortin Pathway (open) • RM-4930-034; A 2-Stage (Open-Label Run-in followed by Randomized Withdrawal), Double-Blind, Placebo-Controlled, Phase 2 Study of Setmelanotide in Patients with Specific Gene Defects in the Melanocortin-4 Receptor Pathway (will open soon) • RM-493-035; A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melanocortin-4 Receptor Pathway (will open soon)

Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) Adolescent Bariatrics: Assessing Health Benefits and Risk (Teen-LABS)

(08/2020 - present)

This project is to assess the short and longer-term safety and efficacy of bariatric surgery in adolescents compared to adults, our site is one of the five Teen-LABS clinical centers nationwide.